Empagliflozin Patent Expiration
Empagliflozin is Used for reducing cardiovascular risk and treating type 2 diabetes, heart failure, and chronic kidney disease with empagliflozin. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Empagliflozin Patents
Given below is the list of patents protecting Empagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jardiance |
US9949998 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Dec 11, 2034 | Boehringer Ingelheim |
| Jardiance |
US9949997 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Nov 17, 2034 | Boehringer Ingelheim |
| Jardiance |
US10258637 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Jardiance |
US11090323 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Jardiance | US9949998 | Pharmaceutical composition, methods for treating and uses thereof | Jun 11, 2034 | Boehringer Ingelheim |
| Jardiance | US9949997 | Pharmaceutical composition, methods for treating and uses thereof | May 17, 2034 | Boehringer Ingelheim |
| Jardiance | US10258637 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Jardiance | US11090323 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Jardiance | US11666590 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Jardiance | US11813275 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Jardiance | US11833166 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Jardiance | US10406172 | Pharmaceutical composition, methods for treating and uses thereof | Jun 15, 2030 | Boehringer Ingelheim |
| Jardiance |
US8551957 (Pediatric) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Apr 14, 2030 | Boehringer Ingelheim |
| Jardiance | US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Oct 14, 2029 | Boehringer Ingelheim |
| Jardiance |
US7579449 (Pediatric) | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Feb 01, 2029 | Boehringer Ingelheim |
| Jardiance | US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Aug 01, 2028 | Boehringer Ingelheim |
| Jardiance |
US7713938 (Pediatric) | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Oct 15, 2027 | Boehringer Ingelheim |
| Jardiance | US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Apr 15, 2027 | Boehringer Ingelheim |
Empagliflozin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Empagliflozin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Empagliflozin has 1 clinical trial that has been verified in 2024.
Empagliflozin Generic API Manufacturers
Several generic applications have been filed for Empagliflozin.
Given below is the list of companies who have filed for Empagliflozin generic, along with the locations of their manufacturing plants worldwide.
1. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Empagliflozin. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Discontinued | ORAL | N/A | Aug 3, 2022 |
| 25MG | tablet | Discontinued | ORAL | N/A | Aug 3, 2022 |